Type 2 diabetes mellitus (T2DM) is intrinsically connected to overweight and obesity. It is a complex metabolic disorder that predisposes patients to, and is associated with, cardiovascular disease. In addition to the triumvirate of core defects associated with T2DM (involvement of the pancreatic beta cell, the muscle, and the liver), other mechanisms including hyperglucagonemia, accelerated gastric emptying, and incretin defi ciency/resistance are also involved. This has led to the development of incretinbased therapies, such as glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. These newer therapies have benefi cial effects on glycosylated hemoglobin A1c (HbA1c) levels, weight, and pancreatic beta-cell function.
T he prevalence of type 2 diabetes mellitus (T2DM) is increasing exponentially worldwide. According to the Centers for Disease Control and Prevention, more than 23 million Americans had diabetes in 2007. 1 Globally, the prevalence of diabetes, of which T2DM accounts for 90% to 95% of cases, 1 is expected to increase from 171 million in 2000 to 366 million in 2030. 2 The National Health and Nutrition Examination Survey (NHANES) showed that about 66% of Americans were overweight or obese between [2003] [2004] . 3 Data from a Swedish National Diabetes Register study showed both overweight and obesity as independent risk factors for cardiovascular disease (CVD) in patients with T2DM. 4 This article presents an overview of the evolving concepts of the pathophysiology of T2DM, with a focus on two new therapeutic classes: the glucagon-like peptide-1 (GLP-1) receptor agonists and the dipeptidyl peptidase-4 (DPP-4) inhibitors.
  THE PATHOPHYSIOLOGY OF T2DM
The American Association of Clinical Endocrinologists (AACE) describes T2DM as "a progressive, complex metabolic disorder characterized by coexisting defects of multiple organ sites including insulin resistance in muscle and adipose tissue, a progressive decline in pancreatic insulin secretion, unrestrained hepatic glucose production, and other hormonal defi ciencies." 5 Other defects include accelerated gastric emptying in patients with T2DM, especially those who are obese or who have the disease for a long duration.
   INCRETIN-BASED THERAPIES: GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS
Exenatide is a GLP-1 receptor agonist that is resistant to DPP-4 degradation. Based on preclinical studies, exenatide, which shares a 53% amino acid sequence identity with human GLP-1, is approximately 5,500 times more potent than endogenous GLP-1 in glucose lowering. 14, 15 Among the acute actions of exenatide is glucose-dependent insulinotropism, the end result of which may be a reduced risk of hypoglycemia. 16 This contrasts with insulin secretagogues (eg, sulfonylureas), which increase insulin secretion regardless of glucose concentrations.
Exenatide received US Food and Drug Administration (FDA) approval in 2005 and is indicated for the treatment of patients with T2DM. 13, 17 Exenatide is administered BID as a subcutaneous (SC) injection in doses of 5 or 10 μg within 1 hour before the two major meals of the day, which should be eaten about 6 hours apart. 18 Approved in 2006, sitagliptin was the fi rst DPP-4 inhibitor indicated for adjunctive therapy to lifestyle modifi cations for the treatment of patients with T2DM. 17 The recommended dosage of oral sitagliptin is 100 mg QD. A single-tablet formulation of the combination of sitagliptin and metformin was approved by the FDA in 2007. 19 Another DPP-4 inhibitor, saxagliptin, was approved in July 2009 for treatment of patients with T2DM either as monotherapy or in combination with metformin, sulfonylurea, or a thiazolidinedione (TZD). 20 The DPP-4 inhibitor vildagliptin is approved in the European Union and Latin America but not in the United States. Vildagliptin is available as a 50-or 100-mg daily dosage; it has been recommended for use at 50 mg QD in combination with a sulfonylurea or at 50 mg BID with either metformin or a TZD. 18    GLP-1 RECEPTOR AGONISTS AND DPP-4 INHIBITORS IN DEVELOPMENT Exenatide is currently being evaluated as a once-weekly formulation. 21, 22 Compared with the BID formulation, exenatide once weekly has been shown to produce signifi cantly greater improvements in glycemic control, with similar reductions in body weight and no increased risk of hypoglycemia. 21 Also undergoing regulatory review is the partly DPP-4-resistant acylated GLP-1 receptor agonist liraglutide. 13 Liraglutide, a human analogue GLP-1 receptor agonist, has 97% linear amino acid sequence homology to human GLP-1. 23, 24 Based on its prolonged degradation time and resulting 10-to 14-hour half-life, liraglutide is anticipated to be dosed once daily. 13, 25, 26 Other GLP-1 receptor agonists and DPP-4 inhibitors are in varying stages of development. 27 Albiglutide is a long-acting GLP-1 receptor agonist that is generated by the genetic fusion of a DPP-4-resistant GLP-1 to human albumin. Based on pharmacokinetic studies, albiglutide has a half-life of 6 to 8 days. AVE0010, an exendin-4-based GLP-1 receptor agonist, was shown in a 28-day T2DM clinical trial to have an affi nity four times greater than native GLP-1 for the human GLP-1 receptor. 27 Taspoglutide (R1583), a human analogue GLP-1 receptor agonist, was evaluated in three randomized, placebo-controlled studies as a GLP-1 receptor agonist. Alogliptin, a DPP-4 inhibitor currently in development, has been shown to be safe and effective in studies as monotherapy and in combination with other antidiabetes agents. Table 1 summarizes the data on the effects of the GLP-1 receptor agonists on glucose lowering based on glycosylated hemoglobin (HbA1c) mean changes from baseline, body weight, and hypoglycemia. Eleven studies were identifi ed for exenatide, including three pivotal trials, [31] [32] [33] three insulin-comparator studies, [34] [35] [36] one long-term study, 37 one monotherapy study (a use for which it is not currently indicated), 38 one head-to-head study with a DPP-4 inhibitor, 39 and two studies with exenatide once weekly (which is currently investiga-
THERAPEUTIC ADVANCES tional). 21, 22 Five primary effi cacy studies with liraglutide were also identifi ed. 23, 25, 26, 40, 41 Table 2 summarizes the corresponding data for the DPP-4 inhibitors. Ten studies with sitagliptin were identifi ed, including four monotherapy studies, [42] [43] [44] [45] one head-to-head study with a GLP-1 receptor agonist, 39 and fi ve studies in which sitagliptin was used in combination or as add-on therapy. [46] [47] [48] [49] [50] Five saxagliptin studies are reviewed, including two in which saxagliptin was used in combination with metformin and one in combination with glyburide. [51] [52] [53] [54] [55] Six studies with vildagliptin were reviewed, [56] [57] [58] [59] [60] [61] but no trials specifi c to the single-tablet formulation of sitagliptin plus metformin were identifi ed.
Effects on HbA1c and weight GLP-1 receptor agonists reduced HbA1c. Based on the studies reviewed in Table 1 , exenatide BID reduced baseline HbA1c by a maximum of Ϫ1.5% at 30 weeks. 21, 31, 32 Exenatide has demonstrated sustained reductions in HbA1c of Ϫ0.8% for up to 3.5 years in an open-label extension trial. 37 Even greater reductions in HbA1c (Ϫ1.4% at 15 weeks and Ϫ1.9% at 30 weeks) have been reported with the once-weekly formulation under clinical development. 21, 22 Liraglutide, another GLP-1 receptor agonist under development, has reported HbA1c reductions from baseline up to Ϫ1.67% at 14 weeks, 40, 41 up to Ϫ1.1% at 26 weeks, 23, 26 and up to Ϫ1.14% at 52 weeks. 25 The reductions quoted generally between a GLP-1 receptor then 10 μg BID SC for 1 wk ST: Ϫ19 mg/dL (FPG) ST: Ϫ0.3 kg hypoglycemic events agonist and a DPP-4 inhibitor, in ST: 100 mg QD PO for 2 wk (P = .3234) (P = .0056) with E or ST patients receiving MET N = 61/crossover study with two treatment periods of 2 wk preceded by 1-wk PL lead-in and no interval washout 25 In this review, only exenatide has been assessed in insulincomparator studies, where it was shown to reduce weight compared with the insulin analogues, which led to weight gain. [34] [35] [36] Hypoglycemia. Patients receiving exenatide experienced lower rates of hypoglycemia (up to 17%) than patients treated with either insulin glargine or insulin aspart (~25%). 34, 36 The rate of hypoglycemia with exenatide is comparable to that seen with metformin (up to 21%) in a systematic review of oral antidiabetes agents conducted by the Agency for Healthcare Research and 20 Although used in Latin America and the European Union, vildagliptin has yet to receive regulatory approval in the United States. 
THERAPEUTIC ADVANCES
Quality. 62 No major hypoglycemic events were reported in the liraglutide studies reviewed. The incidence of hypoglycemia reported with DPP-4 inhibitors (Table 2) is also low (2% or less in most studies). The glucosedependent mechanisms of the incretin-based therapies minimizes the risk of hypoglycemia.
DPP-4 inhibitors and sustained HbA1c reduction. The effects of the DPP-4 inhibitors on HbA1c and weight, either as monotherapy or in combination with other agents, were evaluated in studies ranging in duration from 12 to 52 weeks (Table 2) . No studies were identifi ed that compared the glycemic control effects of DPP-4 inhibitors and insulin analogues. Sitagliptin led to a mean reduction in HbA1c from baseline of up to Ϫ0.65% at 12 weeks, 43, 45 up to Ϫ0.48% at 18 weeks, 44 up to Ϫ0.85% at 24 weeks, 42, 46, 47, 50 up to Ϫ1.0% at 30 weeks, 49 and up to Ϫ0.67% at 52 weeks. 48 Saxagliptin mean reductions in HbA1c ranged from Ϫ0.43% to Ϫ1.17%. [51] [52] [53] [54] Data from four 24-week T2DM studies [56] [57] [58] [59] [60] showed vildagliptin reducing HbA1c up to Ϫ1.4% at 24 weeks, with the greatest reduction in a study that involved drug-naïve patients with a relatively short duration of disease (mean, 1.2 years). 59 Reductions in HbA1c of Ϫ1.0% were sustained in a 52-week study 61 and its 52-week extension. Table 2) . The effects of sitagliptin on weight ranged from a loss of Ϫ1.5 kg 48 at 52 weeks to a gain of +1.8 kg at 24 weeks. 50 Weight changes with saxagliptin ranged from a mean reduction of Ϫ1.8 kg 53 to a gain of +0.7 kg. 51 Two vildagliptin studies showed varying effects on weight ranging from a loss of up to Ϫ1.8 kg from baseline 56 to a gain of up to +1.3 kg 57 relative to placebo, both at 24 weeks.
Potential for CV risk reduction
Potentially benefi cial effects on CV risk factors, including blood pressure (ie, reduction) and lipid concentrations (ie, differential effects on low-density lipoprotein and high-density lipoprotein cholesterol), were identifi ed in seven GLP-1 receptor studies-three with exenatide (two with exenatide BID, 37, 38 and one with the investigational exenatide once weekly 21 ) and four with liraglutide. 23, 25, 26, 41 For the DPP-4 inhibitors, three studies were identifi ed-two with sitagliptin 45, 50 and one with vildagliptin 61 -in which potentially benefi cial effects on CV risk factors were demonstrated.The data have been encouraging, although the clinical implications have yet to be fully understood.
Head-to-head comparison
A recent study compared the effects of the GLP-1 receptor agonist exenatide and the DPP-4 inhibitor sitagliptin on postprandial glucose (PPG) concentrations, insulin and glucagon secretion, gastric intake, and caloric intake. 39 Although limited by a short treatment duration (2 weeks), the study showed that the GLP-1 receptor agonist had a greater effect than the DPP-4 inhibitor in reducing PPG concentrations, a more potent effect in increasing insulin secretion and decreasing postprandial glucagon secretion, and a relatively greater effect in reducing caloric intake; and that it decreased the rate of gastric emptying (sitagliptin had no effect). These differences suggest that exenatide may provide a greater degree of GLP-1 receptor activation than the more physiologic concentrations of GLP-1 reached with DPP-4 inhibition. 39 Results of a scintigraphic study showed that exenatide substantially slows the gastric emptying that is accelerated in patients with T2DM. This could be another benefi cial mechanism in treating postprandial glycemia.
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Adverse effects
Exenatide has shown effects on hepatic injury markers (ie, improvement in alanine and aspartate aminotransferases) for up to 3.5 years of treatment. 37 For the GLP-1 receptor agonist and DPP-4 inhibitor studies reviewed, the adverse events were generally mild and included nausea and vomiting, nasopharyngitis, and mild hypoglycemia.
Meta-analysis conclusions
The published clinical trial data presented in this review expand the body of evidence on the safety and effi cacy of incretin-based therapy in patients with T2DM. These data include the results of a meta-analysis by Amori et al, 17 which examined randomized controlled trials of 12 weeks' or longer duration that compared incretin-based therapy with placebo or other diabetes medications and reported HbA1c changes in adults with T2DM. The meta-analysis showed that incretinbased therapies reduced HbA1c more than placebo (weighted mean difference, Ϫ0.97% [95% confi dence interval (CI), Ϫ1.13% to Ϫ0.81%] for GLP-1 receptor agonists and Ϫ0.74% [95% CI, Ϫ0.85% to Ϫ0.62%] for DPP-4 inhibitors) and were noninferior to other antidiabetes agents. Treatment with a GLP-1 receptor agonist (ie, exenatide) caused weight loss (Ϫ1.4 kg and Ϫ4.8 kg vs placebo and insulin, respectively) while DPP-4 inhibitors (ie, sitagliptin, vildagliptin) were weight neutral. 
Beta-cell function
Evidence regarding the effects of incretin-based therapies, particularly the exendin-4 GLP-1 receptor agonists, on beta-cell function in patients with T2DM continues to accumulate. When assessing long-term (1 year) exenatide treatment in patients with T2DM, a trial (n = 69) comparing exenatide with the basal insu-lin analogue insulin glargine showed that exenatide and insulin glargine resulted in similar reductions in HbA1c (Ϫ0.8% vs Ϫ0.7%; P = .55). 64 However, exenatide signifi cantly reduced body weight while insulin glargine resulted in weight gain (Ϫ3.6 kg vs +1.0 kg; P < .0001). In terms of beta-cell function, arginine-stimulated C-peptide secretion during hyperglycemia increased 2.46-fold from baseline after 52 weeks of exenatide treatment compared with 1.31-fold with insulin glargine treatment (P < .0001). 64 With respect to the direct beta-cell effects of liraglutide, a preclinical study reported that liraglutide improved glucose homeostasis in marginal mass islet transplantation in diabetic mice. 65 In this study, liraglutide was shown, in a mouse model, to reduce the time to normoglycemia after islet cell transplantation (median time, 1 vs 72.5 days; P < .0001). The effects of liraglutide on beta-cell function also were assessed in 13 patients with T2DM. After 7 days of treatment, liraglutide improved beta-cell function, which was associated with improvement in glucose concentration. 66 Liraglutide improved potentiation of insulin secretion during the fi rst meal, owing in part to restoration of the potentiation peak (which is markedly blunted in T2DM), in a phenomenon similar to that observed with exenatide. 67 Benefi cial effects on beta-cell function have also been reported with DPP-4 inhibitors. In a model-based analysis of patients with T2DM, it was shown that sitagliptin improved basal, static, and dynamic responsiveness of pancreatic beta cells to glucose. The results were observed when sitagliptin was administered both as an add-on to metformin therapy and as monotherapy. 68 A 52-week, double-blind, randomized, parallel-group study compared vildagliptin 50 mg/day and placebo in 306 patients with T2DM and mild hyperglycemia (HbA1c, 6.2% to 7.5%). Vildagliptin was shown to signifi cantly increase fasting insulin secretory tone, glucose sensitivity, and rate sensitivity, all of which are aspects of betacell function.
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Summary
Based on the ability of incretin-based therapies to address various disease mechanisms, including betacell defects (ie, hyperglycemia), hormone-related abnormalities (ie, hyperglucagonemia, incretin deficiency/resistance), and accelerated gastric emptying (especially with GLP-1 receptor agonists); their favorable effects on weight (reduction with GLP-1 receptor agonists and neutral with DPP-4 inhibitors); their benefi cial effects on CV risk factors; and their good safety profi le (ie, hypoglycemia risk comparable with metformin), these agents could be considered therapeutic advances for the treatment of patients with T2DM.
   INCRETIN-BASED THERAPIES IN GUIDELINES
AND ALGORITHMS The 2007 AACE medical guidelines for clinical practice for the management of diabetes recognized the place of the incretin-based therapies and included them among the pharmacologic options. 5 Exenatide was specifi cally recommended for combination therapy with metformin, a sulfonylurea (secretagogue), a sulfonylurea plus metformin, or a TZD. Sitagliptin was recommended for use as monotherapy or in combination with metformin or a TZD. 5 In 2009, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes convened a consensus panel to produce an algorithm for the initiation and adjustment of therapy for patients with T2DM. In this algorithm, GLP-1 receptor agonists were considered appropriate in certain clinical scenarios (eg, when hypoglycemia was an issue or weight loss was a major consideration during treatment). However, the groups also noted a need for more data on long-term safety and the cost of treatment with incretin-based therapies. 70 The AACE and the American College of Endocrinology recently developed "road maps" for managing patients with T2DM. In patients with T2DM who are naïve to therapy, DPP-4 inhibitors are among the recommended fi rst options when the initial HbA1c is 6.0% to 7.0% and as a combination therapy component when HbA1c reaches 7.0% to 9.0%. In patients who have already received monotherapy for 2 to 3 months and whose HbA1c is 6.5% to 8.5%, treatment options include combination therapy with a DPP-4 inhibitor and metformin or a TZD. Another option includes the initiation of treatment with a GLP-1 receptor agonist in combination with a TZD, with metformin or a sulfonylurea, or with metformin and a sulfonylurea. 71 The role of GLP-1 receptor agonist therapies and their incorporation into T2DM treatment algorithms was noted at the 2008 annual meeting of the ADA. In the Banting lecture, Ralph A. DeFronzo, MD, advocated the early use of triple-drug therapy with metformin, exenatide, and a TZD in the management of patients with T2DM. 9   CONCLUSION T2DM, which is linked to weight gain and obesity, is a complex disease that predisposes patients to and is associated with CVD. A better understanding and appreciation of the role of the incretin system in the pathogenesis of T2DM has led to the development of incretin-based therapies, such as the GLP-1 receptor agonists and DPP-4 inhibitors. As more experimental and clinical evidence becomes available, subtle nuances are emerging that distinguish the roles of these two therapeutic classes.
